menu
    • menu
    [{"orgOrder":0,"company":"Adcendo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ADCE-T02","moa":"||Tissue factor","graph1":"Oncology","graph2":"Phase I","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adcendo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adcendo \/ Inapplicable"},{"orgOrder":0,"company":"Adcendo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ADCE-T02","moa":"||Tissue factor","graph1":"Oncology","graph2":"Phase I","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adcendo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adcendo \/ Inapplicable"},{"orgOrder":0,"company":"Adcendo","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"ADCE-T02","moa":"||Tissue factor","graph1":"Oncology","graph2":"Phase I","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adcendo \/ TCGX","highestDevelopmentStatusID":"6","companyTruncated":"Adcendo \/ TCGX"},{"orgOrder":0,"company":"Adcendo","sponsor":"Duality Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||uPARAP","graph1":"Oncology","graph2":"Preclinical","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adcendo \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Adcendo \/ Adcendo"},{"orgOrder":0,"company":"Adcendo","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Inapplicable","moa":"||CIDEB","graph1":"Oncology","graph2":"Preclinical","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adcendo \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Adcendo \/ Adcendo"},{"orgOrder":0,"company":"Adcendo","sponsor":"Duality Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||CIDEB","graph1":"Oncology","graph2":"Preclinical","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adcendo \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Adcendo \/ Adcendo"},{"orgOrder":0,"company":"Adcendo","sponsor":"Novo Seeds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Inapplicable","moa":"||uPARAP","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adcendo \/ Novo Seeds","highestDevelopmentStatusID":"1","companyTruncated":"Adcendo \/ Novo Seeds"},{"orgOrder":0,"company":"Adcendo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adcendo \/ Inapplicable"},{"orgOrder":0,"company":"Adcendo","sponsor":"Multitude Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"ADCE-T02","moa":"||Tissue factor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Adcendo","highestDevelopmentStatusID":"5","companyTruncated":"Adcendo \/ Adcendo"},{"orgOrder":0,"company":"Adcendo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ADCE-D01","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adcendo \/ Inapplicable"},{"orgOrder":0,"company":"Adcendo","sponsor":"Dawn Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Dawn Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Adcendo \/ Dawn Biopharma"},{"orgOrder":0,"company":"Adcendo","sponsor":"Pontifax Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Pontifax Venture Capital","highestDevelopmentStatusID":"7","companyTruncated":"Adcendo \/ Pontifax Venture Capital"},{"orgOrder":0,"company":"Adcendo","sponsor":"Duality Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Adcendo","highestDevelopmentStatusID":"2","companyTruncated":"Adcendo \/ Adcendo"}]

    Find Clinical Drug Pipeline Developments & Deals by Adcendo

    Menu

    Adcendo

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADCE-T02,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adcendo ApS Gets FDA IND Clearance for Phase I Tiffany-01 Trial of ADCE-T02

                            Details : ADCE-T02 is a highly differentiated anti-TF ADC, and the first ADC with a Topoisomerase I inhibitor-based linker/payload, being investigated for advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            February 26, 2025

                            Lead Product(s) : ADCE-T02,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 29, 2025

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Biocytogen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

                            Details : Under the terms of the agreement, Biocytogen will use cutting-edge platforms for antibody discovery to support Adcendo’s innovative ADC drug development for cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 16, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Biocytogen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADCE-T02,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : TCGX

                            Deal Size : $135.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ADC Biotech Adds on $135M Series B

                            Details : The proceeds will be used to advance Company’s first-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programs.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            November 25, 2024

                            Lead Product(s) : ADCE-T02,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : TCGX

                            Deal Size : $135.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Duality Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Duality Biologics Expands Adcendo Collaboration via Strategic License Agreement

                            Details : Adcendo exercises its option to utilize Duality's platform to further enhance its first-in-class ADC pipeline and develop highly differentiated novel ADCs for the treatment of hard-to-treat cancers.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 25, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Duality Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADCE-T02,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : ADCE-T02,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADCE-T02,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Multitude Therapeutics

                            Deal Size : $1,000.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Adcendo & Multitude Announce Agreement on First-in-class ADC Targeting Tissue Factor

                            Details : Under this license agreement, Adcendo will obtain the exclusive development and commercialization rights of ADCE-T02 for treating non-small cell lung cancer, colorectal cancer, etc.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            August 20, 2024

                            Lead Product(s) : ADCE-T02,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Multitude Therapeutics

                            Deal Size : $1,000.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADCE-D01,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adcendo IND Cleared for Phase I/II Trial of ADCE-D01 Targeting uPARAP in Cancer

                            Details : ADCE-D01 is an antibody-drug conjugate targeting the uPARAP receptor. Currently, it is being evaluated for the treatment of Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            August 10, 2024

                            Lead Product(s) : ADCE-D01,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Dawn Biopharma

                            Deal Size : $106.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Adcendo ApS Extends Series A Financing to EUR 98M for First-in-Class ADC Pipeline

                            Details : Adcendo plans to advance the development of its first-in-class ADC pipeline assets and expand the development strategy for its lead uPARAP program in soft tissue sarcoma and other mesenchymal cancers.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 30, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Dawn Biopharma

                            Deal Size : $106.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed

                            Adcendo

                            Denmark arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Duality Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand...

                            Details : Under the agreement, new targets will be evaluated with Duality’s linker-payload platform, designed to generate ADCs with superior safety profiles, sustainable payload delivery and release in tumors, and efficient bystander killing of antigen low and n...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 30, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Duality Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth